Waist to hip ratio modifies the cardiovascular risk of lipoprotein (a): Insights from MESA
Progress in Cardiovascular Diseases,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 1, 2025
Language: Английский
The prevalence, patients' characteristics, and hyper-Lp(a)-emia risk factors in the polish population. The first results from the PMMHRI-Lp(a) registry
Progress in Cardiovascular Diseases,
Journal Year:
2024,
Volume and Issue:
86, P. 54 - 61
Published: Aug. 25, 2024
The
knowledge
on
the
prevalence
of
elevated
lipoprotein(a)
(Lp(a)),
patients'
characteristics,
and
nongenetic
risk
factors
is
scarce
in
some
regions
including
Poland,
largest
Central
Eastern
European
country.
Thus,
we
aimed
to
present
results
from
Lp(a)
registry
established
Poland's
2nd
largest,
supra-regional
hospital
-
Polish
Mother's
Memorial
Hospital
Research
Institute
(PMMHRI).
Language: Английский
Refining cardiovascular risk assessment: The interplay of lipoprotein (a) and waist-to-hip ratio
Annalisa Filtz,
No information about this author
Martha Gulati
No information about this author
Progress in Cardiovascular Diseases,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 1, 2025
Language: Английский
Prevalence and role of elevated serum lipoprotein(a) in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI
Russian Cardiology Bulletin,
Journal Year:
2025,
Volume and Issue:
20(1), P. 39 - 39
Published: April 14, 2025
Objective.
Serum
lipoprotein(a)
(Lp(a))>50
mg/dl
is
associated
with
higher
risk
of
cardiovascular
diseases
and
complications.
The
aim
this
study
was
to
assess
the
prevalence
elevated
Lp(a)
in
patients
acute
myocardial
infarction
(MI)
various
regions
Russian
Federation
(RF),
as
well
target
level
low-density
lipoprotein
cholesterol
(LDL
cholesterol)
these
patients.
Material
methods.
REGION–IM
(Russian
Registry
Acute
Myocardial
Infarction)
a
multiple-center
prospective
observational
study.
follow-up
included
3
stages:
hospital-stay,
6
12
months
after
inclusion
register.
Demographic
anamnestic
data,
information
about
MI
were
entered
into
registration
card.
analyzed
1.623
(22%)
from
40
Federation.
There
1.173
(72%)
men
450
(28%)
women
aged
60
years
(range
30—94).
Results.
Mean
serum
12.4
2
—
722.2).
This
value
significantly
(15.5
versus
10.8
mg/dl,
p<0.05)
STEMI
(12.9
p<0.05).
>50
recorded
414
(26%)
patients,
50—100
12.9%,
101—180
2.9%,
>
180
10.3%
Conclusion.
50
every
fourth
patient
while
extreme
elevation
(>180
mg/dl)
tenth
Screening
at
least
once
lifetime
will
allow
determining
category
extremely
high
complications
including
those
LDL-C.
Language: Английский
Exploring research trends and hotspots on PCSK9 inhibitor studies: a bibliometric and visual analysis spanning 2007 to 2023
Ping Lai,
No information about this author
Shuquan Xu,
No information about this author
Ziyou Liu
No information about this author
et al.
Frontiers in Cardiovascular Medicine,
Journal Year:
2024,
Volume and Issue:
11
Published: Nov. 22, 2024
Background
Following
the
identification
of
proprotein
convertase
subtilisin/kexin
type
9
(PCSK9)
inhibitors,
research
in
this
area
has
experienced
significant
growth.
However,
a
thorough
bibliometric
analysis
burgeoning
field
remains
conspicuously
absent.
The
current
study
aims
to
delineate
hotspots
and
anticipate
future
trends
on
PCSK9
inhibitors
employing
analysis.
Methods
A
systematic
search
was
conducted
Web
Science
Core
Collection
(WoSCC)
identify
scholarly
articles
reviews
pertaining
yielding
1,812
documents.
Data
extraction
followed
by
visualization
using
Excel,
VOSviewer,
CiteSpace
software.
Results
total
publications
were
included
final
Ray,
KK
from
UK
most
prolific
author,
Pordy,
R
USA.
USA
led
publication
output
[number
(Np):776]
number
citations
without
self-citations
(Nc)
at
34,289,
as
well
an
H-index
93.
“Cardiovascular
System
Cardiology”
emerged
predominant
subject
area.
Amgen
Journal
Clinical
Lipidology
identified
active
institution
journal,
respectively.
Keywords
such
“lipoprotein(a),”
“bempedoic
acid,”
“percutaneous
coronary
intervention,”
“inclisiran,”
“peripheral
artery
disease,”
“mortality,”
“endothelial
dysfunction”
are
gaining
prominence
field.
Conclusion
is
experiencing
sustained
growth
trajectory.
exerts
considerable
influence
area,
with
expected
feature
more
groundbreaking
studies.
Research
“lipoprotein(a)”,
acid”,
intervention”,
disease”,
poised
become
focal
points
investigation.
Language: Английский
Progress in pediatric cardiology VSI: Cardiovascular disease in pediatrics lipoprotein(a) in atherosclerotic cardiovascular disease, type 2 diabetes, and liver disease
Kent A. Williams,
No information about this author
Molly Augustine,
No information about this author
Eru Sujakhu
No information about this author
et al.
Progress in Pediatric Cardiology,
Journal Year:
2024,
Volume and Issue:
unknown, P. 101775 - 101775
Published: Dec. 1, 2024
Language: Английский